COVID-19News

RDIF partners with Virchow Biotech

200 million doses of Sputnik V will be produced per year 

The Russian Direct Investment Fund (RDIF) and Virchow Biotech (part of the Virchow Group), a leading vaccine and pharmaceutical producers in India, have agreed to produce up to 200 million doses per year of Sputnik V in India.

The technology transfer is expected to be completed in the second quarter of 2021 followed by full-scale commercial production of Sputnik V. Virchow Biotech capacities will help facilitate global supply of Sputnik V to international partners of RDIF.

Kirill Dmitriev, CEO, RDIF commented, “Vaccine partnerships are the only way to overcome the pandemic. The world continues its fight against coronavirus and we see a growing interest in the Sputnik V vaccine as it is one of the most efficient vaccines available. The agreement with Virchow Biotech is an important step to facilitate the full-scale local production of the vaccine in India and to supply our international partners globally.”

Dr Tummuru Murali, MD, Virchow Biotech, said, “We are glad to sign a cooperation agreement with RDIF to produce the Sputnik V coronavirus vaccine. Virchow’s proven capabilities in large scale drug substance manufacturing should help meet the global demand for this vaccine. We are also happy to learn of the positive feedback that this vaccine has been receiving from all сountries.”

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close